Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
stomach cancer
Pharma
Novartis-Argo, Eisai, Henlius—Fierce Pharma Asia
Novartis signed a $5.2 billion siRNA deal with Argo. The FDA approved subcutaneous Leqembi. The Hong Kong exchange censured Henlius and its former CEO.
Angus Liu
Sep 5, 2025 9:00am
FDA limits Keytruda, Opdivo uses in stomach cancer
Jun 9, 2025 10:50am
ASCO: AZ looks to bring immunotherapy to early stomach cancer
Jun 1, 2025 8:00am
AstraZeneca says Imfinzi keeps stomach cancer from coming back
Mar 7, 2025 9:48am
AZ, Daiichi's Enhertu delivers survival win in stomach cancer
Mar 3, 2025 3:43pm
Merck, Eisai combo misses survival goal in GI cancer trial
Jan 24, 2025 10:26am